Chlamydia pneumoniae IgM ELISA

Enzyme immunoassay for the in-vitro-diagnostic qualitative determination of IgM antibodies against Chlamydia pneumoniae in human serum or plasma.

REF RE57051

Σ 96

i 2-8°C

NovaTec Immundiagnostica GmbH
Technologie & Waldpark
Waldstr. 23 A6
D–63128 Dietzenbach, Germany

Distributed by:

IBL INTERNATIONAL GMBH
Flughafenstrasse 52a
D-22335 Hamburg, Germany
Phone: +49 (0)40-53 28 91-0
Fax: +49 (0)40-53 28 91-11
IBL@IBL-International.com
www.IBL-International.com
1. INTRODUCTION

Chlamydiae are no motile, Gram negative and obligatory intracellular growing bacteria which form characteristic inclusions within the cytoplasm of parasitized cells. They are easily visible in the light microscope. Three different Chlamydia species pathogenic for humans are known: Chlamydia trachomatis, Chlamydia pneumoniae and Chlamydia psittaci, and one species only pathogenic for animals (C. pecorum). Chlamydia trachomatis is the most prevalent agent of sexually transmitted diseases worldwide (400-500 million cases) and the number of infections is constantly growing. Pregnant women infected with C. trachomatis may transmit these bacteria during childbirth, causing conjunctivitis or pneumonia in newborns. Untreated cases of chlamydial infection can lead to chronic salpingitis, possibly resulting in ectopic pregnancy or infertility. In males, C. trachomatis is a major cause of non-gonococcal urethritis. A severe problem in Chlamydia infections is the frequent asymptomatic insidious course which may result in the initiation of chronic diseases. In many instances primary infections are not recognized and only the sequelae caused by ascended, persisting agents are diagnosed.

<table>
<thead>
<tr>
<th>Species</th>
<th>Mechanism of infection</th>
<th>Disease</th>
<th>Diagnostics</th>
</tr>
</thead>
<tbody>
<tr>
<td>C. trachomatis</td>
<td>Direct or sexual transmission: The primary site of infection usually is the mucous membrane of the eye or the urogenital tract</td>
<td>Lymphogranuloma venereum (LGV) Trachoma Inclusion conjunctivitis of neonates and adults; Cervicitis, salpingitis, urethritis, epididymitis, proctitis and pneumonia of newborns</td>
<td>Serology, PCR</td>
</tr>
<tr>
<td>C. pneumoniae</td>
<td>Infiltration of the mucous membrane of the respiratory tract</td>
<td>Respiratory diseases discussed: endocarditis, coronary heart diseases</td>
<td>Microscopy</td>
</tr>
<tr>
<td>C. psittaci</td>
<td>Inhalation of feces from infected birds; contact with infected avian viscera</td>
<td>Ornithosis (Psittacosis)</td>
<td></td>
</tr>
</tbody>
</table>

Infection may be identified by
- Microscopy: Giemsa stain
- PCR
- Serology: Detection of antigens by ELISA
  Detection of antibodies by IF, EIA, ELISA

2. INTENDED USE

The IBL Chlamydia pneumoniae IgM-ELISA is intended for the qualitative determination of IgM class antibodies against Chlamydia pneumoniae in human serum or plasma (citrate).

3. PRINCIPLE OF THE ASSAY

The qualitative immunoenzymatic determination of IgM-class antibodies against Chlamydia pneumoniae is based on the ELISA (Enzyme-linked Immunosorbent Assay) technique. Microtiter strip wells are precoated with Chlamydia pneumoniae antigens to bind corresponding antibodies of the specimen. After washing the wells to remove all unbound sample material horseradish peroxidase (HRP) labelled anti-human IgM conjugate is added. This conjugate binds to the captured Chlamydia pneumoniae-specific antibodies. The immune complex formed by the bound conjugate is visualized by adding Tetramethylbenzidine (TMB) substrate which gives a blue reaction product. The intensity of this product is proportional to the amount of Chlamydia pneumoniae-specific IgM antibodies in the specimen. Sulphuric acid is added to stop the reaction. This produces a yellow endpoint colour. Absorbance at 450 nm is read using an ELISA microwell plate reader.

4. MATERIALS

4.1. Reagents supplied

- **Chlamydia pneumoniae Coated Wells (IgM):** 12 breakapart 8-well snap-off strips coated with Chlamydia pneumoniae antigen; in resealable aluminium foil.
- **IgM Sample Diluent ***:** 1 bottle containing 100 ml of buffer for sample dilution; containing antihuman-IgG; pH 7.2 ± 0.2; coloured green; ready to use; white cap.
- **Stop Solution:** 1 bottle containing 15 ml. Ready to use sulphuric acid, 0.2 mol/L; red cap.
- **Washing Solution (20x conc.):** 1 bottle each containing 50 ml of a 20-fold concentrated buffer (pH 7.2 ± 0.2) for washing the wells; white cap.
- **Chlamydia pneumoniae anti-IgM Conjugate***:** 1 bottle containing 20 ml of peroxidase labelled rabbit antibody to human IgM; coloured red, Ready to use; black cap.
- **TMB Substrate Solution:** 1 bottle containing 15 ml 3,3',5,5'-tetramethylbenzidine (TMB); ready to use; yellow cap.
- **Chlamydia pneumoniae IgM Positive Control***:** 1 bottle containing 2 ml; coloured yellow; ready to use; red cap.
- **Chlamydia pneumoniae IgM Cut-off Control***:** 1 bottle containing 3 ml; coloured yellow; ready to use; green cap.
- **Chlamydia pneumoniae IgM Negative Control***:** 1 bottle containing 2 ml; coloured yellow; ready to use; blue cap.

* contains 0.1 % Bronidox L after dilution
** contains 0.2 % Bronidox L
*** contains 0.1 % Kathon

4.2. Materials supplied

- 1 Strip holder
- 1 Cover foil
- 1 Test protocol

4.3. Materials and Equipment needed

- ELISA microwell plate reader, equipped for the measurement of absorbance at 450/620 nm
- Incubator 37°C
5. STABILITY AND STORAGE
The reagents are stable up to the expiry date stated on the label when stored at 2...8 °C.

6. REAGENT PREPARATION

It is very important to bring all reagents, samples and controls to room temperature (20...25°C) before starting the test run!

6.1. Coated snap-off strips
The ready to use breakapart snap-off strips are coated with Chlamydia pneumoniae antigen. Store at 2...8°C. Immediately after removal of strips, the remaining strips should be reveals in the aluminium foil along with the desiccant supplied and stored at 2...8 °C; stability until expiry date.

6.2. Chlamydia pneumoniae anti-IgM Conjugate
The bottle contains 20 ml of a solution with anti-human-IgM horseradish peroxidase, buffer, stabilizers, preservatives and an inert red dye. The solution is ready to use. Store at 2...8°C. After first opening stability until expiry date when stored at 2...8°C.

6.3. Controls
The bottles labelled with Positive, Cut-off and Negative Control contain a ready to use control solution. It contains 0.1% Kathon and has to be stored at 2...8°C. After first opening stability until expiry date when stored at 2...8°C.

6.4. IgM Sample Diluent
The bottle contains 100 ml phosphate buffer, anti-human-IgG, stabilizers, preservatives and an inert green dye. It is used for the dilution of the patient specimen. The solution contains antihuman IgG class antibodies to eliminate competitive inhibition from specific IgG class antibody to remove rheumatoid factor. This ready to use solution has to be stored at 2...8°C. After first opening stability until expiry date when stored at 2...8°C.

6.5. Washing solution (20xconc.)
The bottle contains 50 ml of a concentrated buffer, detergents and preservatives. Dilute washing solution 1+19; e.g. 10 ml washing solution + 190 ml fresh and germ free redistilled water. The diluted buffer is stable for 5 days at room temperature. Crystals in the solution disappear by warming up to 37 °C in a water bath. After first opening the concentrate is stable until the expiry date.

6.6. TMB Substrate Solution
The bottle contains 15 ml of a tetramethylbenzidine/hydrogen peroxide system. The reagent is ready to use and has to be stored at 2...8°C, away from the light. The solution should be colourless or could have a slight blue tinge. If the substrate turns into blue, it may have become contaminated and should be thrown away. After first opening stability until expiry date when stored at 2...8°C.

6.7. Stop Solution
The bottle contains 15 ml 0.2 M sulphuric acid solution (R 36/38, S 26). This ready to use solution has to be stored at 2...8°C. After first opening stability until expiry date.

7. SPECIMEN COLLECTION AND PREPARATION

Use human serum or plasma (citrate) with this assay. If the assay is performed within 5 days after sample collection, the specimen should be kept at 2...8°C; otherwise they should be aliquoted and stored deep-frozen (-70 to -20°C). If samples are stored frozen, mix thawed samples well before testing. Avoid repeated freezing and thawing. Heat inactivation of samples is not recommended.

7.1. Sample Dilution
Before assaying all samples should be diluted 1+100 with IgM Sample Diluent. Dispense 10µl sample and 1 ml IgM Sample Diluent into tubes to obtain a 1+100 dilution and thoroughly mix with a Vortex.

8. ASSAY PROCEDURE

8.1. Test Preparation
Please read the test protocol carefully before performing the assay. Result reliability depends on strict adherence to the test protocol as described. The following test procedure is only validated for manual procedure. If performing the test on ELISA automatic systems we recommend to increase the washing steps from three to five and the volume of washing solution from 300µl to 350µl to avoid washing effects. Prior to commencing the assay, the distribution and identification plan for all specimens and controls should be carefully established on the result sheet supplied in the kit. Select the required number of microtiter strips or wells and insert them into the holder.

Please allocate at least:

1 well (e.g. A1) for the substrate blank,
1 well (e.g. B1) for the negative control,
2 wells (e.g. C1+D1) for the cut-off control and
1 well (e.g. E1) for the positive control.

It is left to the user to determine controls and patient samples in duplicate, if necessary.

Perform all assay steps in the order given and without any appreciable delays between the steps. A clean, disposable tip should be used for dispensing each control and sample.

Adjust the incubator to 37° ± 1°C.
1. Dispense 100µl controls and diluted samples into their respective wells. Leave well A1 for substrate blank.
2. Cover wells with the foil supplied in the kit.
3. **Incubate for 1 hour ± 5 min at 37±1°C.**
4. When incubation has been completed, remove the foil, aspirate the content of the wells and wash each well three times with 300µl of washing solution. Avoid overflows from the reaction wells. The soak time between each wash cycle should be >5 sec. At the end carefully remove remaining fluid by tapping strips on tissue paper prior to the next step!
   *Note: Washing is critical! Insufficient washing results in poor precision and falsely elevated absorbance values.*
5. Dispense 100µl Chlamydia pneumoniae anti IgM Conjugate into all wells except for the blank well (e.g. A1). Cover with foil.
6. **Incubate for 30 min 37±1°C.**
7. Repeat step 4.
8. Dispense 100µl TMB Substrate Solution into all wells
9. **Incubate for exactly 30 min at room temperature in the dark.**
10. Dispense 100µl Stop Solution into all wells in the same order and at the same rate as for the TMB Substrate Solution.
    *Note: Highly positive patient samples can cause dark precipitates of the chromogen! These precipitates have an influence when reading the optical density. Predilution of the sample with physiological sodium chloride solution, for example 1+1, is recommended. Then dilute the sample 1+100 with dilution buffer and multiply the results in U by 2.
11. Measure the absorbance of the specimen at 450/620 nm within 30 min after addition of the Stop Solution.

8.2. Measurement

Adjust the ELISA Microwell Plate Reader to zero using the substrate blank in well A1.
If due to technical reasons - the ELISA reader cannot be adjusted to zero using the substrate blank in well A1, subtract the absorbance value of well A1 from all other absorbance values measured in order to obtain reliable results!

**Measure the absorbance** of all wells at **450 nm** and record the absorbance values for each control and patient sample in the distribution and identification plan.

Dual wavelength reading using 620 nm as reference wavelength is recommended.
Where applicable calculate the **mean absorbance values** of all duplicates.

9. RESULTS

9.1. Assay validation criteria

In order for an assay to be considered valid, the following criteria must be met:
- **Substrate blank** in A1: Absorbance value < 0.100.
- **Negative control** in B1: Absorbance value < 0.200 and < cut-off
- **Cut-off control** in C1 and D1: Absorbance value 0.150 – 1.30.
- **Positive control** in E1: Absorbance value > cut-off.

If these criteria are not met, the test is not valid and must be repeated.

9.2. Calculation of Results

The cut-off is the mean absorbance value of the Cut-off control determinations.

*Example: Absorbance value Cut-off control 0.44 + absorbance value Cut-off control 0.42 =0.86 / 2 = 0.43
Cut-off = 0.43*

9.3. Interpretation of Results

Samples are considered **POSITIVE** if the absorbance value is higher than 10% over the cut-off.

Samples with an absorbance value of 10% above or below the cut-off should not be considered as clearly positive or negative ➔ **grey zone**

It is recommended to repeat the test again 2 - 4 weeks later with a fresh sample. If results in the second test are again in the grey zone the sample has to be considered **NEGATIVE**.

Samples are considered **NEGATIVE** if the absorbance value is lower than 10% below the cut-off.

9.3.1. Results in Units

Patient (mean) absorbance value × 10

Cut-off

Example: 1.204 × 10 = 28 U

0.43

<table>
<thead>
<tr>
<th>Cut-off</th>
<th>Grey zone</th>
<th>Positive</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 U</td>
<td>&lt;9 U</td>
<td>&gt;11 U</td>
</tr>
</tbody>
</table>

V 13022012
10. SPECIFIC PERFORMANCE CHARACTERISTICS

10.1. Precision

<table>
<thead>
<tr>
<th>Interassay</th>
<th>Mean (U)</th>
<th>CV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pos. Serum</td>
<td>21.6</td>
<td>8.25</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Intraassay</th>
<th>Mean (E)</th>
<th>CV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pos. Serum</td>
<td>1.16</td>
<td>4.01</td>
</tr>
</tbody>
</table>

10.2. Diagnostic Specificity

The diagnostic specificity is defined as the probability of the assay of scoring negative in the absence of the specific analyte. It is > 95%.

10.3. Diagnostic Sensitivity

The diagnostic sensitivity is defined as the probability of the assay of scoring positive in the presence of the specific analyte. It is 83.3%.

10.4. Interferences

Interferences with hemolytic, lipemic or icteric sera are not observed up to a concentration of 10 mg/ml hemoglobin, 5 mg/ml triglycerides and 0.2 mg/ml bilirubin.

Note: The results refer to the groups of samples investigated; these are not guaranteed specifications.

11. LIMITATIONS OF THE PROCEDURE

Bacterial contamination or repeated freeze-thaw cycles of the specimen may affect the absorbance values. Diagnosis of an infectious disease should not be established on the basis of a single test result. A precise diagnosis should take into consideration clinical history, symptomatology as well as serological data. In immunosuppressed patients and newborns serological data only have restricted value. The Chlamydia pneumoniae antigen which is coated on the plates is comprised of elementary bodies. A cross reaction with Chlamydia trachomatis cannot be excluded with sera containing antibodies to LPS and MOMP.

12. PRECAUTIONS AND WARNINGS

- In compliance with article 1 paragraph 2b European directive 98/79/EC the use of the in vitro diagnostic medical devices is intended by the manufacturer to secure suitability, performances and safety of the product. Therefore the test procedure, the information, the precautions and warnings in the instructions for use have to be strictly followed. The use of the testkits with analyzers and similar equipment has to be validated. Any change in design, composition and test procedure as well as for any use in combination with other products not approved by the manufacturer is not authorized; the user himself is responsible for such changes. The manufacturer is not liable for false results and incidents for these reasons. The manufacturer is not liable for any results by visual analysis of the patient samples.
- Only for in-vitro diagnostic use.
- All components of human origin used for the production of these reagents have been tested for anti-HIV antibodies, anti-HCV antibodies and HBsAg and have been found to be non-reactive. Nevertheless, all materials should still be regarded and handled as potentially infectious.
- Do not interchange reagents or strips of different production lots.
- No reagents of other manufacturers should be used along with reagents of this test kit.
- Do not use reagents after expiry date stated on the label.
- Use only clean pipette tips, dispensers, and lab ware.
- Do not interchange screw caps of reagent vials to avoid cross-contamination.
- Close reagent vials tightly immediately after use to avoid evaporation and microbial contamination.
- After first opening and subsequent storage check conjugate and control vials for microbial contamination prior to further use.
- To avoid cross-contamination and falsely elevated results pipette patient samples and dispense conjugate without splashing accurately to the bottom of wells.
- The ELISA is only designed for qualified personnel who are familiar with good laboratory practice.

WARNING: In the used concentration Bronidox L has hardly any toxicological risk upon contact with skin and mucous membranes!
WARNING: Sulphuric acid irritates eyes and skin. Keep out of the reach of children. Upon contact with the eyes, rinse thoroughly with water and consult a doctor!

12.1. Disposal Considerations

Residues of chemicals and preparations are generally considered as hazardous waste. The disposal of this kind of waste is regulated through national and regional laws and regulations. Contact your local authorities or waste management companies which will give advice on how to dispose hazardous waste.

BIBLIOGRAPHY

SCHEME OF THE ASSAY
Chlamydia pneumoniae IgM-ELISA

Assay Preparation

Prepare reagents and samples as described.
Establish the distribution and identification plan for all specimens and controls on the result sheet.
Select the required number of microtiter strips or wells and insert them into the holder.

Assay Procedure

<table>
<thead>
<tr>
<th>Substrate blank (e.g. A1)</th>
<th>Negative control</th>
<th>Positive control</th>
<th>Cut-off control</th>
<th>Sample (diluted 1+100)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative control</td>
<td>-</td>
<td>100µl</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Positive control</td>
<td>-</td>
<td>-</td>
<td>100µl</td>
<td>-</td>
</tr>
<tr>
<td>Cut-off control</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>100µl</td>
</tr>
<tr>
<td>Sample (dilated 1+100)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>100µl</td>
</tr>
</tbody>
</table>

Cover wells with foil supplied in the kit
**Incubate for 1 h at 37°C**
Wash each well three times with 300µl of washing solution

| Conjugate                | 100µl            | 100µl           | 100µl          | 100µl                |

Cover wells with foil supplied in the kit
**Incubate for 30 min at 37°C**
Wash each well three times with 300µl of washing solution

| TMB Substrate           | 100µl            | 100µl           | 100µl          | 100µl                |

**Incubate for exactly 30 min at room temperature in the dark**

| Stop Solution           | 100µl            | 100µl           | 100µl          | 100µl                |

Photometric measurement at 450 nm (reference wavelength: 620 nm)
Symbols / Symbole / Symbôles / Símbolos / Σύµβολα

REF  Cat.-No.: / Kat.-Nr.: / No.- Cat.: / Cat.-No.: / N.º Cat.: / N.–Cat.: / Αριθμός-Κατ.:  
LOT  Lot-No.: / Chargen-Bez.: / No. Lot: / Lot-No.: / Lote N.º: / Lotto n.: / Αριθμός -Παραγωγή:  
Use by: / Verwendbar bis: / Utiliser à: / Usado por: / Usar até: / Da utilizzare entro: / Χρησιμοποιείται από:  
Concentrate / Konzentrat / Concentré / Concentrar / Concentrado / Concentrato / Συµπύκνωµα  
Lyophilized / Lyophilisat / Lyophilisé / Liofilizado / Liofilizado / Liofilizzato / Λυοφιλιασµένο  
In Vitro Diagnostic Medical Device. / In-vitro-Diagnostikum. / Appareil Médical pour Diagnostics In Vitro. / Equipamento Médico de Diagnóstico In Vitro. / Dispositivo Medico Diagnostico In vitro. / Ιατρική συσκευή για In-Vitro Διάγνωση.  
Read instructions before use. / Arbeitsanleitung lesen. / Lire la fiche technique avant emploi. / Lea las instrucciones antes de usar. / Ler as instruções antes de usar. / Leggere le istruzioni prima dell’uso. / Διαβάστε τις οδηγίες πριν την χρήση.  
Keep away from heat or direct sun light. / Vor Hitze und direkter Sonneneinstrahlung schützen. / Garder à l'abri de la chaleur et de toute exposition lumineuse. / Manténgase alejado del calor o la luz solar directa. / Non esporre ai raggi solari. / Να φυλάσσεται μακριά από θερµότητα και άµεση επαφή µε το φως του ηλίου.  
Manufacturer: / Hersteller: / Fabricant: / Productor: / Fabricante: / Fabbricante: / Παραγωγός:  
Caution! / Vorsicht! / Attention! / ¡Precaución! / Cuidado! / Attenzione! / Προσοχή!  
Symbols of the kit components see MATERIALS SUPPLIED.  
Die Symbole der Komponenten sind im Kapitel KOMPONENTEN DES KITS beschrieben.  
Voir MATERIEL FOURNI pour les symbôles des composants du kit.  
Símbolos de los componentes del juego de reactivos, vea MATERIALES SUMINISTRADOS.  
Para símbolos dos componentes do kit ver MATERIAIS FORNECIDOS.  
Per i simboli dei componenti del kit si veda COMPONENTI DEL KIT.  
Για τα σύµβολα των συστατικών του κιτ συµβουλευτείτε το ΠΑΡΕΧΟΜΕΝΑ ΥΛΙΚΑ.  

### IBL AFFILIATES WORLDWIDE

<table>
<thead>
<tr>
<th>IBL International GmbH</th>
<th>IBL International Corp.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flughafenstr. 52A, 22335 Hamburg, Germany</td>
<td>194 Wildcat Road, Toronto, Ontario M3J 2N5, Canada</td>
</tr>
<tr>
<td>Tel.: + 49 (0) 40 532891 -0 Fax: -11</td>
<td>Tel.: +1 (416) 645 -1703 Fax: -1704</td>
</tr>
<tr>
<td>E-MAIL: <a href="mailto:IBL@IBL-International.com">IBL@IBL-International.com</a></td>
<td>E-MAIL: <a href="mailto:Sales@IBL-International.com">Sales@IBL-International.com</a></td>
</tr>
</tbody>
</table>

**LIABILITY:** Complaints will be accepted in each mode –written or vocal. Preferred is that the complaint is accompanied with the test performance and results. Any modification of the test procedure or exchange or mixing of components of different lots could negatively affect the results. These cases invalidate any claim for replacement. Regardless, in the event of any claim, the manufacturer’s liability is not to exceed the value of the test kit. Any damage caused to the kit during transportation is not subject to the liability of the manufacturer.